The Analyst Landscape: 4 Takes On Crescent Capital BDC
Portfolio Pulse from Benzinga Insights
Crescent Capital BDC (NASDAQ:CCAP) has received mixed analyst ratings over the past three months, with a consistent average price target of $19. Analysts have varied in their ratings from 'Buy' to 'Equal-Weight', reflecting differing views on the company's performance. Despite a decline in revenue, Crescent Capital BDC shows strong profitability and financial health with high net margins and ROE.
September 30, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Crescent Capital BDC has received mixed analyst ratings, with a stable average price target of $19. Despite a recent revenue decline, the company maintains strong profitability and financial health, as indicated by high net margins and ROE.
The mixed analyst ratings and stable price target suggest a neutral short-term impact on CCAP's stock price. The company's strong financial metrics, such as high net margins and ROE, provide a positive outlook, but the recent revenue decline may offset this, leading to a balanced view.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100